Envista Holdings Co. (NYSE:NVST) Shares Sold by Marathon Asset Management Ltd

Marathon Asset Management Ltd decreased its position in Envista Holdings Co. (NYSE:NVST) by 6.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,066,303 shares of the company’s stock after selling 70,047 shares during the quarter. Marathon Asset Management Ltd owned 0.62% of Envista worth $20,568,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in NVST. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Envista during the third quarter valued at $31,000. Huntington National Bank lifted its holdings in shares of Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after buying an additional 949 shares during the last quarter. Venturi Wealth Management LLC lifted its holdings in shares of Envista by 528.4% during the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after buying an additional 1,638 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Envista by 50.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after purchasing an additional 728 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after buying an additional 538 shares during the period.

Envista Price Performance

Shares of NVST opened at $19.93 on Monday. Envista Holdings Co. has a 1-year low of $15.15 and a 1-year high of $23.00. The firm has a fifty day simple moving average of $20.29 and a two-hundred day simple moving average of $19.69. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44. The firm has a market cap of $3.43 billion, a PE ratio of -3.07, a P/E/G ratio of 1.27 and a beta of 1.34.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. On average, equities analysts anticipate that Envista Holdings Co. will post 1 EPS for the current year.

Wall Street Analyst Weigh In

NVST has been the topic of a number of research reports. Morgan Stanley boosted their price objective on Envista from $19.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday, February 6th. Piper Sandler boosted their price objective on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a research note on Tuesday, February 25th. Jefferies Financial Group upped their price objective on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Finally, Wells Fargo & Company increased their price target on Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a report on Thursday, February 6th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $20.21.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.